CRPC w/ Bone Metastases VL

Anti-resorptive Therapy to Reduce Skeletal-Related Events Risk in Men with Bone-Metastatic CRPC Presentation - Chris Parker

Chris Parker presents on the utilization of antiresorptive therapy to reduce skeletal-related events (SRE) risk in men with bone metastatic castration-resistant prostate cancer (mCRPC) at the Advanced Prostate Cancer Consensus Conference (APCCC 2019). Dr. Parker's presentation was part of a debate featured during the Bone and Bone Metastases Session. He summarized the evidence base in 2002 after t...

Sequencing Treatments in Metastatic Prostate Cancer - Evan Yu

Evan Yu and Alicia Morgans share in a discussion on where we are in understanding treatment options for metastatic hormone-sensitive prostate cancer (mHSPC) and sequencing treatments after progression from nmCPRC to mCRPC. The conversation includes selecting and evaluating patients with mCRPC and how treatments are selected for these patients. Dr. Yu discusses the opportunities to individualize tr...

Real World Treatment Experience with Radium-223 - Daniel George

Dan George concentrated on the patient experience in the treatment of metastatic castration-resistant prostate cancer (mCRPC). He described a typical treatment timeline where a new patient presents with elevated PSA is initially treated with androgen deprivation therapy (ADP) to reduce testosterone feeding tumor growth. While the patient may initially respond with a reduced PSA, it is most common...

Contemporary Treatment of Castration-Resistant Prostate Cancer (CRPC) - Fred Saad

Charles Ryan, MD, and Fred Saad, MD have a clinical discussion on the full spectrum of castration-resistant prostate cancer (CRPC) from inception in both symptomatic vs asymptomatic patients from the evolution of abiraterone acetate and enzalutamide to the time point of integrating therapies earlier into CRPC. Dr. Saad discusses the spectrum of development of the disease and the optimal way for cl...

Bone Health in Prostate Cancer - A Conversation with Neal Shore and Oliver Sartor

Neal Shore and Oliver Sartor have a conversation on bone-targeted agent therapies in prostate cancer, specifically focusing on the ALSYMPCA phase three trial; the design, findings, the addition of radium-223 and what this trial has led to today. They review a few other current ongoing trials including the PEACE III single arm trial and other current approaches in understanding combination therapie...

Prostate Cancer Osteomimicry in Circulating Tumor Cells in Men with Metastatic Castration Resistant Prostate Cancer (mCRPC) - Andrew Armstrong

Andrew Armstrong and Alicia Morgans, discuss the PROPHECY trial, a prospective trial of circulating tumor cells, evaluating two current assays: the EPIC AR-V7 Nuclear Protein CTC and the Hopkins AR-V7 Adnatest. The conversation evolves to a discussion of the data from Armstrong's recent work shared at the 2018 ASCO GU meeting: measuring osteomimicry in three levels: RNA, DNA, and protein, potentia...

Updates on Health-Related Quality-of-Life (HRQoL) analyses in GU Oncology - Cora Sternberg

Cora Sternberg highlights from a number of key treatments in GU Oncology in a discussion with Alicia Morgans. Results from the only Phase 3 health-related quality-of-life (HRQoL) analyses in urothelial carcinoma from the KEYNOTE-045 study delivers results for patients who received 2 nd line therapy. A relevant discussion follows on a Phase 2 trial investigating 3 different dosing regimens of radiu...

The State of Nuclear Medicine in the Treatment of Prostate Cancer - Interview with Oliver Sartor

Charles Ryan, MD, and Oliver Sartor, MD discuss bone health in the treatment of prostate cancer and then transition to discuss the novel theranostic opportunities that are in development for the treatment of prostate cancer including Lutetium-177 PSMA and Actinium PSMA-225. Lastly, they have a concise conversation about DNA mutations in prostate cancer and the implications of germ-line and somatic...

Imaging Modality and Recommendations Included in RADAR 3: Interview with Phillip Koo

(Length of Discussion: 13 min) Phillip Koo, MD, FACS joins Alicia Morgans, MD, MPH to discuss the RADAR 3 recommendations in regards to imaging and detecting metastatic disease in prostate cancer. Biographies: Phillip J. Koo, MD, FACS Alicia Morgans, MD, MPH Related Content: A Clinician’s Guide to Next Generation Imaging in Patients with Advanced Prostate Cancer (Prostate Cancer Radiographic Asses...

Whole Body MRI Scanning and Disease Progression - Anwar Padhani

Professor Anwar Padhani discusses the value of whole body MRI scanning in diagnosing disease progression at the Radiological Society of North America (RSNA) 2017 conference. Dr. Padhani discusses the biggest advantage of using whole body MRI scanning versus bone or CT scans, which is the ability to detect metastatic disease in bone. Whole body MRI scans are also accurate in detecting castrate-resi...

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.